Kiniksa Pharmaceuticals, Ltd. announced the launch of a Named Patient Program for ARCALYST, a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1a) and interleukin-1 beta (IL-1ß) signaling. The Named Patient Program for ARCALYST was launched in partnership with the specialist services company, WEP Clinical. The program is designed to ensure that physicians outside the U.S. can request ARCALYST on behalf of individual patients who have recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), or deficiency of IL-1 receptor antagonist (DIRA) but reside in countries where ARCALYST is not currently commercially available.